LRRC38

Across TCGA pan-cancer cohorts, LRRC38 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LRRC38 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher LRRC38 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LRRC38 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

READ, ESCA, and LIHC are the cancer types where LRRC38 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.218	0.824	<.001	30	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	15	view →
LIHC	OS	Median	All	0.098	0.774	.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	DFS	Median	All	1.000	0.500	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LRRC38–READ (DFS)

Open the READ breakdown →